Hospital Universitario Austral - Pilar

Av. Juan Domingo Perón 1500, Pilar, Buenos Aires

Select an option

I am a doctor

I am a sponsor

Our team

Medical staff

Silvio Carricondo

Gustavo Daniel Kusminsky

Sofia Blotta

Pablo Maid

Luis Ignacio Daverede

Andrés Nicolás Atamañuk

Hernán Amartino

Marcelo Silva

Cristina Alonso

Diego Arufe

Gabriela Marinsalta

David Veron

Open studies

Myeloproliferative syndromes

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment - MYF3001 - Geron CorporationSee more

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) - Merck Sharp & Dohme LLCSee more

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) - Merck Sharp & Dohme LLCSee more

Bladder Cancer

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin - VOLGA - AstraZenecaSee more

Cholangitis

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis - ELFIDENCE - IpsenSee more

Kidney cancer

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma - STELLAR-304 - ExelixisSee more

Lupus

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus - POETYK SLE-2 - Bristol-Myers SquibbSee more

Multiple myeloma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) - MagnetisMM-32 - PfizerSee more

Skin cancer

A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) - V940-007 - Merck Sharp & Dohme LLCSee more